| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.2 | 1e-06 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.25 | 1e-06 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.26 | 1e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.23 | 1e-05 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.17 | 4e-05 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-05 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.23 | 5e-05 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.16 | 7e-05 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0002 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0002 |